• Feifei Yang, Pihong Liu, Xiaosi Zhang, Zhe Zhang, Hao Lu, and Naizhi Geng.
• Heilongjiang University of Chinese Medicine, Harbin, China.
• Medicine (Baltimore). 2022 Dec 9; 101 (49): e32190e32190.

ObjectiveTo investigate the mechanism of action of Datura metel in the treatment of sinus bradycardia based on network pharmacology and molecular docking.MethodsThe active ingredients and targets of Datura metel were collected by TCMSP database, and the Cytoscape software was used to map to show the interrelationship. Use 5 databases: GeneCards, PharmGKB, OMIM, DisGeNET, and Drugbank to obtain targets related to sinus bradycardia; establish a protein-to-protein interaction network with the help of the STRING platform; GO and Kyoto Encyclopedia of Genes and Genomes analysis of the selected core targets using the Metascape platform; Finally, the AutoDock platform was used for molecular docking and the results were displayed through Pymol.Results27 kinds of active ingredients of the drug were screened, including 10 kinds of main ingredients; 198 drug targets and 1059 disease targets. There are 54 targets of action in the treatment of sinus bradycardia, of which 19 targets such as AKT1, IL6, TNF, and VEGFA are the core targets of Datura metel in the treatment of sinus bradycardia. Kyoto Encyclopedia of Genes and Genomes obtained 18 results suggesting that AGE-RAGE, hepatitis C, relaxin, and JAK-STAT may be key signaling pathways. Molecular docking shows that most components of the drug have good docking ability with the core target, indicating that the prediction results have certain reliability.ConclusionThis study preliminarily explores the potential active ingredients and possible mechanisms of action of Datura metel in the treatment of sinus bradycardia and provides a basis for in-depth investigation of its medicinal material basis and mechanism of action.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…